INBRX-101 Concentrate for Solution for Infusion 50mg/ml clinical trials

A Phase 2, Double-blind, Randomized, Active-control, Parallel Group Study to Assess the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and safety of SAR447537 (INBRX-101) Compared to Plasma Derived Apha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Adults with Alpha-1 Antitrypsin Deficiency (AATD) Emphysema

This study compares a new medicine, INBRX-101, with standard treatment for Alpha-1 Antitrypsin Deficiency (AATD) emphysema. It looks at how the medicines work in the body, their effects, and if they are safe, to help people with this lung condition.